Policy & Regulation
SQZ Biotechnologies to Make First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with Stemcell Technologies on Research-Use-Only System to Fuel Preclinical Research
10 May 2022 - - US-based clinical-stage biotechnology company SQZ Biotechnologies (NYSE: SQZ) will present data from the first non-clinical studies of its point-of-care manufacturing system at the 2022 American Society for Gene and Cell Therapy (ASGCT) annual meeting on May 18, the company said.

The data will demonstrate an ability to produce SQZ cell therapy candidates with comparable or improved performance relative to conventional clean room manufacturing processes. In addition, SQZ announced a collaboration with Stemcell Technologies to co-develop and commercialize a research-use-only microfluidic intracellular delivery system.

The new RUO system will be based on SQZ's Cell Squeeze technology and will offer the life sciences community access to a unique cell engineering capability to advance preclinical research.

SQZ said these activities support its mission to unlock the full potential of cell therapies for multiple therapeutic areas.

The company said its Cell Squeeze technology has enabled the development of three oncology therapeutic candidates in active Phase 1/2 clinical trials.

In addition to these programs, the company intends to file its first IND using the POC system for a SQZ TAC clinical candidate against celiac disease in the first half of 2023.

The Cell Squeeze technology has also led to a number of preclinical developments in the areas of infectious disease and cell regeneration.

SQZ's automated POC manufacturing system in development integrates, among other things, cell isolation, cell washing, intracellular delivery, and product filling. The system is designed to process patient material within a closed, single-use sterile disposable kit.

The prototype system offers the potential to be operated outside of a clean room--which could ultimately allow decentralized cell therapy manufacturing by SQZ POC systems in a variety of care settings.

SQZ will present data from the initial non-clinical studies of the POC system at ASGCT.

Stemcell Technologies will present data from the first functional study findings for the RUO system at the ASGCT annual meeting.

The data will demonstrate an ability to efficiently deliver cargoes to primary immune cell types. SQZ will also present new cell engineering data in hematopoietic stem cells using mRNA and CRISPR/Cas9 at the meeting.

SQZ Biotechnologies company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in oncology, autoimmune and infectious diseases, as well as additional exploratory initiatives to support future pipeline growth.

The company's proprietary Cell Squeeze technology offers the ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics.

Stemcell Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services.

Stemcell offers cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.


Related Headlines